Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.24 USD | -4.74% | -13.40% | +124.15% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
Evolution of the average Target Price on Arcutis Biotherapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Arcutis Biotherapeutics, Inc.
Needham & Co. | |
Mizuho Securities | |
Morgan Stanley | |
JonesTrading Institutional Services | |
Goldman Sachs | |
Truist Securities | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- ARQT Stock
- Consensus Arcutis Biotherapeutics, Inc.